Related Experiment Videos
Developments in therapeutics for pulmonary arterial hypertension
M R Wilkins1, G M O Møller, X Ren
1Section on Clinical Pharmacology Imperial College, Hammersmith Hospital, London, UK. m.wilkins@ic.ac.uk
Minerva Cardioangiologica
|July 11, 2002
Summary
Recent discoveries in pulmonary hypertension (PH) reveal genetic links and new treatments. Understanding BMPR2 and ALK-1 gene mutations offers insights into primary pulmonary hypertension (PPH) and guides the development of targeted therapies like bosentan and sildenafil.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Pulmonary hypertension (PH) management has historically been challenging due to limited understanding and treatment options.
- Recent advances have shed light on the genetic underpinnings of primary pulmonary hypertension (PPH).
Purpose of the Study:
- To review the evolving landscape of pulmonary hypertension management.
- To highlight recent insights into the pathogenesis of PPH.
- To discuss novel therapeutic agents and future directions.
Main Methods:
- Review of current literature on pulmonary hypertension.
- Examination of genetic mutations associated with PPH (BMPR2, ALK-1).
- Analysis of the mechanism and efficacy of new pharmacological agents (bosentan, sildenafil).
Main Results:
- Mutations in BMPR2 and ALK-1 genes are implicated in the pathogenesis of PPH.
- These genes encode TGF-b receptor superfamily members crucial for pulmonary vascular health.
- Orally active drugs, bosentan and sildenafil, show promise in treating PH with some selectivity.
Conclusions:
- Genetic discoveries are transforming the understanding of PPH.
- New pharmacological agents offer improved treatment options for PH.
- Continued research promises further advancements in managing pulmonary hypertension.